The Bottom Line

Frontal fibrosing alopecia (FFA) is a scarring hair loss condition that causes a progressive receding of the front and temple hairline, usually with loss of eyebrows and sometimes eyelashes. It predominantly affects postmenopausal women (90% female, typically age 40–70) and accounts for 4–12% of scarring alopecias in developed countries. The damage is permanent because the immune system destroys the hair follicles — which is why early treatment is critical. With treatment, about 50–60% of patients can stabilize the condition. Oral minoxidil has emerged as a key first-line therapy, slowing progression in about 75% of treated patients in clinical studies.

What Is Frontal Fibrosing Alopecia?

Frontal fibrosing alopecia (FFA) is a type of scarring alopecia — meaning it causes permanent hair loss by destroying hair follicles and replacing them with scar tissue. It was first described by dermatologist Dr. Kossard in 1994 and has since been recognized as one of the most common scarring alopecias in women in developed countries.

FFA is classified as a lymphocytic scarring alopecia. "Lymphocytic" means the cause of follicle destruction is immune cells called lymphocytes (specifically CD8+ T cells), which attack the hair follicles. Once a follicle is destroyed and replaced by fibrosis (scar tissue), it cannot regenerate. This is what makes FFA a medical urgency — every month of untreated or inadequately treated disease means more permanent follicle loss.

The prevalence of FFA has increased dramatically since the 1990s. It now accounts for the most common scarring alopecia seen in women in Europe and North America, though the reasons for this rise remain unclear. Possible contributing factors include hormonal changes (declining estrogen with menopause), cosmetic product exposures, UV radiation, and genetic predisposition.

Who Gets FFA?

  • 90% of patients are female, typically postmenopausal (age 40–70), though premenopausal women and men are increasingly diagnosed
  • Prevalence is 8–12% among women with scarring alopecia in developed nations
  • Higher rates reported in Europe and North America compared to Asia
  • Genetic predisposition exists — a family history of FFA increases risk
  • Some studies suggest environmental factors including UV exposure and cosmetic product use (such as SPF-containing facial creams or hair products) may play a role, but evidence remains inconclusive

What Are the Signs of FFA?

Receding Hairline

The primary sign of FFA is progressive recession of the frontal and temporal hairlines. Unlike male-pattern baldness (which typically shows diffuse thinning behind the hairline), FFA causes the hairline boundary itself to move backward — often in a more geometric, defined band. The skin over the bald zone may appear pale, atrophic (thinned), and slightly shiny, reflecting fibrosis and permanent follicle loss beneath.

Eyebrow Loss — A Key Diagnostic Clue

Loss of eyebrows is a hallmark feature of FFA and one of the most diagnostically important signs. The outer third of the eyebrow (the lateral portion) is typically lost first, then the loss progresses medially. Patients sometimes present to their doctor about eyebrow loss before they notice the hairline recession. The combination of frontal hairline recession and eyebrow loss is virtually pathognomonic (specific to) FFA and should prompt urgent dermatology evaluation.

Eyelash Loss

Loss of eyelashes (madarosis) occurs in advanced cases but is less universal than eyebrow loss.

Other Signs

  • A "lonely hair" sign — isolated hairs remaining just in front of the main receding hairline, the last follicles before complete destruction
  • Facial hair loss in some women — small, fine hairs on the face (sideburns, temples) may also recede
  • Pruritus (itching) or a burning sensation at the hairline in some patients — others have no symptoms
  • Body hair loss — leg or arm hair thinning may accompany FFA in some patients

Why Is FFA Permanent?

In FFA, CD8+ T lymphocytes attack the bulge region of the hair follicle — the area that contains the stem cells responsible for follicle regeneration. Once this zone is destroyed and replaced by fibrosis, regeneration is no longer possible. Unlike alopecia areata (where follicles are put into a dormant but intact state and can regrow), FFA causes physical destruction and permanent loss of the follicular structure. This is the critical difference between scarring and non-scarring alopecias.

How Is FFA Diagnosed?

Diagnosis requires correlation of clinical features with dermoscopy and histopathology:

  • Clinical examination — frontal and temporal hairline recession with eyebrow loss is highly suggestive
  • Dermoscopy — the dermatologist uses a magnifying device to examine the hairline. Characteristic findings include a peripilar cast (scaling around the hair shaft), absence of follicular openings in the bald zone, and yellow dots (fibrotic follicles that resemble sesame seeds)
  • Scalp biopsy — a small skin sample from the active advancing hairline margin is processed and examined under the microscope. It reveals the characteristic dense perifollicular lymphocytic infiltrate, follicular destruction, and fibrosis that confirms FFA. Biopsy from the already-bald zone gives less diagnostic information — the active zone at the advancing edge is key.

Treatment Options

No treatment reverses FFA — the goal is to halt or significantly slow progression and preserve the remaining follicles. Early intervention is critical: the therapeutic window closes as more follicles are destroyed and fibrosis becomes extensive.

Oral Minoxidil (First-Line)

Low-dose oral minoxidil (1–2.5 mg daily) has become a cornerstone of FFA treatment. The landmark Inui et al. 2018 study published in the Journal of the American Academy of Dermatology demonstrated that oral minoxidil significantly slowed progression of FFA in 75% of treated patients, compared to placebo. Regrowth of eyebrow hair occurred in approximately 40% of patients. Response requires 4–6 months of continuous treatment. Minoxidil is generally well-tolerated; side effects at low doses include mild fluid retention and fine facial hair growth (hypertrichosis) in some women.

Topical Treatments

  • Topical finasteride 0.1% solution — applied twice daily to the hairline and eyebrows. Systemic finasteride is less effective in women than men, but topical application may provide local benefit without significant systemic absorption.
  • Topical minoxidil 5% foam or solution — applied twice daily to the hairline and eyebrows, often used alongside oral minoxidil for combined benefit

Corticosteroids

  • Intralesional corticosteroid injection (triamcinolone 2.5–5 mg/mL) into the advancing hairline margin every 4–6 weeks — studies show approximately 50–60% of patients achieve disease stabilization with this approach
  • Oral corticosteroids (prednisone 0.5–1 mg/kg daily, tapered over 2–3 months) — achieve response in 60–70% of patients, but long-term use carries significant risks including immunosuppression, osteoporosis, weight gain, and metabolic complications

Second-Line Systemic Agents

  • Acitretin (isotretinoin family) — 0.5–1 mg/kg daily shows response in 40–50% of patients in case series. Important: acitretin is teratogenic and is contraindicated in women of childbearing potential. Requires monthly liver function and lipid monitoring.
  • Mycophenolate mofetil (500–1000 mg twice daily) — approximately 50% of patients achieve stabilization or improvement in small series
  • Pioglitazone (15–30 mg daily) — a diabetes medication with anti-inflammatory properties; approximately 50% stabilization rate in preliminary studies
  • Cyclosporine — used in refractory cases; response rates of 30–40%

Emerging Therapies

JAK inhibitors (including oral ruxolitinib, baricitinib, and topical JAK inhibitors) are being investigated for FFA. Early case reports and small series suggest benefit, particularly when used early in disease course. Topical JAK inhibitors specifically formulated for scalp application are under active investigation.

Prognosis

Without treatment, FFA progresses relentlessly over 5–10 years or longer, causing extensive frontal and temporal baldness with complete loss of eyebrows and eyelashes in many patients. Some patients plateau at intermediate disease stages, while others progress rapidly.

With early treatment (particularly oral minoxidil and intralesional corticosteroids), approximately 50–60% of patients achieve disease stabilization or modest improvement. Regrowth of hair and eyebrows is typically modest (10–30% improvement in density) but meaningful compared to continued progression. The critical window for intervention appears to be within 3–5 years of disease onset, before extensive fibrosis develops and the disease becomes treatment-resistant.

When to See a Dermatologist

  • Progressive recession of your front hairline, especially over the temples
  • Thinning or loss of the outer portion of your eyebrows
  • The combination of frontal hairline recession and eyebrow loss — this is urgent
  • Itching, burning, or tenderness at the hairline
  • You have been diagnosed with lichen planopilaris and want to know if FFA is present
  • Any woman over 40 with unexplained frontal hair thinning — FFA should be considered and ruled out

Frequently Asked Questions

Is frontal fibrosing alopecia the same as female-pattern hair loss?

No. While both conditions cause frontal hair loss in women, they are fundamentally different. Female-pattern hair loss (androgenetic alopecia) is non-scarring — follicles thin progressively but are not destroyed, and the condition can be treated with minoxidil and hormonal therapies. FFA is scarring, with permanent follicle destruction, and has a characteristic pattern of hairline recession plus eyebrow loss that distinguishes it. A scalp biopsy and dermoscopy can confirm the difference when clinical features are ambiguous.

Will my eyebrows grow back with treatment?

With early treatment, some eyebrow regrowth is possible — studies show 10–40% improvement in density with oral minoxidil. However, regrowth is not guaranteed, and once eyebrows are completely lost, regrowth is unlikely even with therapy. This is why early diagnosis and treatment is so important: the sooner treatment begins, the more likely some brow hair is preserved.

How quickly does FFA progress?

Disease progression varies considerably. Some patients show slow progression over many years while others progress rapidly over months. Without treatment, extensive frontal baldness typically develops over 5–10 years. With treatment, progression is significantly slowed in the majority of patients.

Can I get a hair transplant for FFA?

Hair transplantation is generally not recommended in active FFA, because the disease will destroy transplanted grafts just as it does the original hair. Transplantation should be considered only after sustained disease stability of at least 1–2 years with treatment. Some centers perform cautious transplantation into stable fibrotic areas where disease activity appears to have completely halted.

  1. Kossard S. Postmenopausal Frontal Fibrosing Alopecia. Arch Dermatol. 1994;130(6):770-774.
  2. Inui S, et al. Efficacy of Low-Dose Oral Minoxidil in Frontal Fibrosing Alopecia. J Am Acad Dermatol. 2018;78(2):S15.
  3. Sperling LC, et al. Scarring Alopecia. Dermatol Clin. 2012;30(1):155-177.
  4. Magro CM, et al. Frontal Fibrosing Alopecia: A Review. J Cutan Pathol. 2014;41(7):534-546.
  5. Harries MJ, et al. Scarring Alopecia Management. Dermatol Clin. 2013;31(1):131-142.
  6. Cramer SM, Schachner LA. Scarring Alopecias: Presentation, Diagnosis, and Management. Semin Cutan Med Surg. 2009;28(1):45-53.
  7. Treeb RM. Scarring Alopecia. Dermatology. 2012;224(2):134-142.
  8. Giesey RL, et al. Frontal Fibrosing Alopecia. J Am Acad Dermatol. 2014;70(4):591-592.

Trusted Resources

Always consult a board-certified dermatologist for diagnosis and personalized treatment recommendations. This article is for educational purposes only.